If you want to get paid promptly in 2019, don't get too comfortable with biopsy codes you've been using for years, says Alexander Miller, M.D., F.A.A.D. Read more from his presentation on coding and office management from the American Academy of Dermatology Annual Meeting in Washington, D.C.
As an expert on coding and office management, Mark D. Kaufmann, M.D., explained important role the AMA's Specialty Society Relative Value Update Committee (RUC) plays in code valuation during his presentation at the American Academy of Dermatology Annual Meeting in Washington, D.C.
The development of new biologics targeting a variety of dermatoses is on the upswing with some treatments coming to the clinic as early as this year, according to April Armstrong, M.D. who discussed the topic at the American Academy of Dermatology Spring Meeting in Washington, D.C.
Psoriasis treatment has expanded dramatically over the past decade, and the growth shows no signs of stopping. Andrew Blauvelt, M.D. discussed new drugs in the pipeline during American Academy of Dermatology Annual Meeting in Washington, D.C.
To help providers have a greater understanding of the efforts of the FDA to ensure all drugs are of pharmaceutical quality, Michael Kopcha, Ph.D., RPh, director of the FDA’s Office of Pharmaceutical Quality presented on the topic during the American Academy of Dermatology’s Annual Meeting in Washington, D.C.
Laura Marquart, M.D., FAAD, medical officer with the FDA’s Center for Devices and Radiological Health (CDRH), reviewed how the FDA approaches, reviews, and approves medical devices integral to dermatologic care at the American Academy of Dermatology’s annual meeting in Washington, D.C. Learn how this process can affect patient care in this article.
While this new class of medications still has a role in treating psoriasis, this physician says the standard for both their efficacy and safety is very high because of the existing, already very effective systemic therapies available today.
Treating chronic inflammatory skin conditions during pregnancy can be difficult because the therapies dermatologists prescribe can affect the unborn infant. See what insights this physician offers on managing chronic inflammatory skin conditions in pregnant patients.